Protease Inhibitor Use in COVID-19
- PDF / 657,825 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 199 Views
COVID-19
Protease Inhibitor Use in COVID-19 Yueqi Song 1 & Wujian Peng 2 & Donge Tang 1 & Yong Dai 1 Accepted: 6 August 2020 # Springer Nature Switzerland AG 2020
Abstract The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to face many new challenges in the treatment and prevention of NCP. Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19. Keywords Novel coronavirus pneumonia . Diagnosis . Treatment . Lopinavir/ritonavir
Backgrounds An ongoing outbreak of a novel disease linked to a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China, at the end of 2019 [1]. From that time point on, COVID-19 has been spreading across almost every country. According to statistics from the National Health Commission, more than 200,000 cases were confirmed cases and 8000 deaths from NCP have been reported throughout the world until March 18, 2020, due to the high contagiousness of NCP [2]. In general, the clinical manifestations of NCP patients include fever, cough, shortness of breath, diarrhea, and vomiting [3].
This article is part of the Topical Collection on COVID-19
Many organizations including medical health service and scientific research center have taken part in the investigation of SARS-CoV-2 to ensure overall recognition of the novel coronavirus and have shared biomedical research results with other scientists [4, 5]. On February 12, 2020, World Health Organization (WHO) designated the new type of pneumonia as COVID-2019 [6], and characterized COVID-19 as a pandemic on 11 March 2020 later [7]. Increasing numbers of colleagues at different hospitals and scientific research institutions have devoted their efforts to this outbreak. Thus, we are very eager to instruct medical workers in other areas on how to diagnose and treat NCP patients under the difficult conditions resulting from the novel coronavirus pneumonia, and our advice is based on the latest reports and the experience of doctors treating COVID-19 in our hospital, with the goal of limiting the impact of the epidemic on every medical worker at the frontline as soon as possible.
* Yong Dai [email protected] 1
2
Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People’s Hospital), 1017 North Road, Dongmen,
Data Loading...
